Archive | Pharmacy RSS feed for this section

People don’t know much about patient portals: Xerox’s 5th EHR study

The Field of Dreams works in nostalgic plotlines about baseball, but as I’ve pointed out since the advent of consumer-facing health technologies, there’s no Field of Dreams effect in health care when it comes to consumer health engagement. U.S. health consumers aren’t using the patient portals that health care providers have built as part of […]

Read full story Comments { 3 }

Pharma industry update – drug spending, R&D costs, generics, and Botox

The U.S. leads in pharmaceutical drug spending. Global growth in pharmaceuticals will spike in 2014, according to the IMS Institute on Healthcare Informatics report on global pharma spending. The U.S. spends more per capita (per person) than any nation in the study, at about $1400 US dollars expected in pharmaceutical spending in 2018, owing to fewer patent […]

Read full story Comments { 0 }

Health-committed consumers look to food to be healthy, wealthy, and wise

There’s an emerging health-committed consumer, one of over 70% of people who believe they’re less healthy than the generations who came before them. 9 in 10 consumers overall believe that what you eat impacts how you feel. Those who are health-committed spend 70% of their grocery budgets on healthy products, read food labels, spend more […]

Read full story Comments { 0 }

Health care as a retail business

The health care industry is undergoing a retail transformation, according to Retail Reigns in Health Care: The rise of consumer power and its organization & workforce implications from Deloitte. Deloitte’s report published in October 2014 focuses on the health insurance business, which is newly-dealing with uninsured people largely unfamiliar with how to evaluate health plan options. […]

Read full story Comments { 1 }

Specialty pharmaceuticals’ costs in the health economic bulls-eye

This past weekend, 60 Minutes’ Leslie Stahl asked John Castellani, the president of PhRMA, the pharmaceutical industry’s advocacy (lobby) organization, why the cost of Gleevec, from Novartis, dramatically increased over the 13 years it’s been in the market, while other more expensive competitors have been launched in the period. (Here is the FDA’s announcement of […]

Read full story Comments { 1 }